PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6807614

Urinary estriol evaluation in obstetrics.

B L Xiao·Q D Lin·J Pan·S L Jiang·Y Q Zhang·M G Li·J F Kang·S Y Weng
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

EstriolFemaleFetal Growth RetardationHumansPre-EclampsiaPregnancyPregnancy ComplicationsPregnancy, ProlongedPrognosisJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B L Xiao, Q D Lin, J Pan, S L Jiang, Y Q Zhang, M G Li, J F Kang, S Y Weng. 1982. Urinary estriol evaluation in obstetrics.. https://pubmed.ncbi.nlm.nih.gov/6807614/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Accuracy of salivary estriol testing compared to traditional risk factor assessment in predicting preterm birth.

OBJECTIVE: The objective was to compare the predictive accuracy (percentage of correct vs incorrect predictions) of salivary estriol levels (SalEst; Biex, Inc, Dublin, Calif) with that of the modified Creasy score for predicting preterm labor followed by preterm delivery. STUDY DESIGN: A triple-blinded prospective trial was conducted at 8 US centers. RESULTS: Among 601 evaluable patients, serial salivary estriol testing correctly predicted the appropriate outcome 91% of the time and the Creasy scoring method correctly predicted the appropriate outcome 75% of the time (McNemar test P <. 001). Among subjects with Creasy scores >/=10 (high-risk group, n = 152), use of salivary estriol testing correctly predicted the end point 87% of the time, compared with only 7.2% correctly predicted by modified Creasy scoring (McNemar test P <.001). CONCLUSION: Salivary estriol assessment was more accurate in predicting outcome than was modified Creasy scoring.

Estriol↗
PubMed1998

Estriol: safety and efficacy.

While conventional hormone replacement therapy provides certain benefits, it is not without significant risks. Estriol has been found to provide some of the protection without the risks associated with stronger estrogens. Depending upon the situation, estriol may exert either agonistic or antagonistic effects on estrogen. Estriol appears to be effective at controlling symptoms of menopause, including hot flashes, insomnia, vaginal dryness, and frequent urinary tract infections. Results of research on its bone-density-maintaining effects have been contradictory, with the most promising results coming from Japanese studies. Estriol's effect on cardiac risk factors has also been somewhat equivocal; however, unlike conventional estrogen prescriptions, it does not seem to contribute to hypertension. Although estriol appears to be much safer than estrone or estradiol, its continuous use in high doses may have a stimulatory effect on both breast and endometrial tissue.

Estriol↗